This inventor holds 2 USPTO granted patents. Top assignees: Funai Kakuhin Kogyo Kabushiki Kaisha, Funai Yakuhin Kogyo Kabushiki Kaisha. Active years: 1983-1984.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1983-1984
Title: Mitsuo Nakamura: Innovator in Anti-Tumor Agents
Introduction
Mitsuo Nakamura is a distinguished inventor based in Kyoto, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anti-tumor agents. With a total of 2 patents, his work has the potential to impact cancer treatment significantly.
Latest Patents
Nakamura's latest patents include innovative ester derivatives of alkoxybenzoyldeoxyfluorouridine. These new derivatives are characterized by a general formula wherein R represents an alkoxy group with 1 to 4 carbon atoms. The compounds are prepared by acylating a 2'-deoxy-3',5'-di-O-alkylcarbonyl-5-fluorouridine with corresponding benzoyl halides. They are particularly useful as active ingredients for anti-tumor agents, especially for oral administration. Another notable patent involves ester derivatives of deoxyfluorouridine, which are also prepared through a similar acylation process and serve as active ingredients for anti-tumor agents.
Career Highlights
Throughout his career, Mitsuo Nakamura has worked with notable companies such as Funai Kakuhin Kogyo and Funai Yakuhin Kogyo. His experience in these organizations has contributed to his expertise in the field of pharmaceuticals and medicinal chemistry.
Collaborations
Nakamura has collaborated with esteemed colleagues, including Setsuro Fujii and Bompei Yasui. These partnerships have fostered innovation and advancement in his research endeavors.
Conclusion
Mitsuo Nakamura's contributions to the development of anti-tumor agents through his innovative patents highlight his role as a key figure in medicinal chemistry. His work continues to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile